Wells Fargo initiated coverage of Exact Sciences with an Overweight rating and $75 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXAS:
- Exact Sciences: 1st patient enrolled in MCED Falcon Registry RWE study
- Exact Sciences price target lowered to $67 from $91 at Benchmark
- Exact Sciences raises FY24 adjusted EBITDA view to $335M-$355M from $325M-$350M
- Exact Sciences reports Q2 EPS (9c), consensus (32c)
- Exact Sciences enters license agreement with TwinStrand Biosciences
Questions or Comments about the article? Write to editor@tipranks.com